NCT06108232 2025-12-19
Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
5 trialsNCT02315768 2025-09-15
Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
University of California, San Diego
Phase 1/2 Completed
NCT03322865 2025-04-04
Obinutuzumab in Marginal Zone Lymphoma
University of Ulm
Phase 2 Active not recruiting
NCT02611908 2019-01-25
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
University of California, San Diego
Phase 1 Withdrawn
NCT02371590 2018-02-23
Lenalidomide and Obinutuzumab for Previously Untreated CLL
University of California, San Diego
Phase 2 Withdrawn